Abstract
Introduction Physicians who treat hemophilia, and especially directors at hemophilia centers, are in a position to be unduly influenced by payments from pharmaceutical companies who make costly hemophilia drugs. It is from this perspective that we analyzed payments made to physicians at hemophilia centers in the US, focusing on center directors.
Materials and methods In a cross-sectional analysis we searched the CDC’s Hemophilia Treatment Center Directory for physicians (2022) and then abstracted general payments for physicians on Open Payments (2018-2020) and calculated one-year average payments. We searched academic websites to determine physician role (hemophilia center director, non-director, or non-center director).
Results There were 420 physicians in the hemophilia physician directory – 270 physicians/professors, 103 directors of hemophilia centers, and 47 other directors. Directors of hemophilia centers had higher median one-year general payments, compared to other directors and physician/professors ($4910 vs $79 vs $87, respectively; p<0.0001). Takeda Pharmaceutical Company Limited, F-Hoffmann La Roche Ltd/Genentech, and Novo Nordisk have the largest hemophilia drug market share and were the three companies with the most payments to physicians.
Conclusions High payments, especially among individuals who have responsibility over the success of hemophilia centers and clinics, may result in competition with the interest of the patients at these centers and clinics.
Competing Interest Statement
Vinay Prasads Disclosures. (Research funding) Arnold Ventures (Royalties) Johns Hopkins Press, Medscape (Honoraria) Grand Rounds/lectures from universities, medical centers, non-profits, professional societies, Youtube, and Substack. (Consulting) UnitedHealthcare. (Speaking fees) Evicore. (Other) Plenary Session podcast has Patreon backers. All other authors have no financial nor non-financial conflicts of interest to report.
Funding Statement
This study was funded by Arnold Ventures
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing Interest: Vinay Prasad’s Disclosures. (Research funding) Arnold Ventures (Royalties) Johns Hopkins Press, Medscape (Honoraria) Grand Rounds/lectures from universities, medical centers, non-profits, professional societies, Youtube, and Substack. (Consulting) UnitedHealthcare. (Speaking fees) Evicore. (Other) Plenary Session podcast has Patreon backers. All other authors have no financial nor non-financial conflicts of interest to report.
Funding: Arnold Ventures.
Data Availability
All data produced are available online at CMS Open Payments (https://openpaymentsdata.cms.gov/) and Centers for Disease Control and Prevention (CDC) Hemophilia Treatment Center Directory (https://dbdgateway.cdc.gov/HTCDirSearch.aspx)
Abbreviations
- CDC
- Centers for Disease Control and Prevention
